Navigation Links
Elusys' Anthim(TM) Dramatically Improves Survival of Animals Treated After Active Anthrax Infection
Date:4/22/2008

Single, Intramuscular (IM) Dose, Protects up to 75 Percent in Primate Study

PINE BROOK, N.J., April 22 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, today announced pivotal animal efficacy results of Anthim(TM), a high-affinity humanized and deimmunized monoclonal antibody targeting the anthrax toxin protective antigen.

Elusys' Anthim is designed as a "just in time" anthrax therapeutic that can be administered by a single, rapid intramuscular injection and has the potential to provide quick protection against the lethal effects of anthrax toxin.

In this study, primates were infected with a highly lethal dose of aerosolized anthrax spores and observed for 60 days. A single IM dose of Anthim provided significant protection (75% survival) when administered at the onset of clinical symptoms of disease (24 hr. post exposure). These results are consistent with a recent rabbit study that showed significant survival of animals treated 24 hours after infection when bacteremia was present.

Elizabeth Posillico, Ph.D., President and Chief Executive Officer of Elusys, commented on the results, "Anthim continues to demonstrate life-saving potential when given in a single, low IM dose after clinical symptoms of infection are present. In earlier animal studies, Anthim provided 100 percent protection when given prior to an anthrax exposure. These results have been consistent across studies whether Anthim was used with or without antibiotics. Our Phase I human safety study demonstrated Anthim is safe and well-tolerated as a monotherapy and as a combined therapy with the antibiotic ciprofloxacin."

Dr. Posillico continued, "Death from the effects of anthrax toxin can occur in a few days if patients are not treated quickly. We are very excited because the results of our studies show that rapid IM treatment with Anthim has the potential to provide 'instant protective immunity' against the anthrax toxin in a bioterrorism emergency. We believe Anthim represents an extremely important medical countermeasure for the treatment of anthrax and should be added to the National Stockpile."

Currently antibiotics represent the only option for the treatment of anthrax infection. Antibiotics may be effective in killing the bacteria, but can still fail to prevent death from the damaging effects of anthrax toxins. In addition, current antibiotics may not be effective at all against antibiotic resistant strains of anthrax.

Anthim Background

Anthim is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. It is being developed for prevention and treatment of inhalation anthrax. Anthim has been granted Fast-Track status and Orphan Drug Designation by the FDA and is being developed under the FDA Animal Rule, a regulatory process specifically designed for the development of medical countermeasures to bioterror threats. Elusys has been awarded $32 million from the National Institutes of Health and the Department of Defense for development of Anthim, of which $12 million was awarded in September 2007 from the National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA), Department of Health and Human Services for advanced development of Anthim. In April of 2007, Anthim was selected to R&D Directions' list of "100 Great Investigational Drugs."

About Elusys

Based in Pine Brook, New Jersey, venture-backed Elusys has two corporate partnerships with MedImmune and Pfizer for development of its HP Antibodies targeting select infectious diseases. Current venture investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures, MedImmune Ventures and Pfizer. For more information please visit http://www.elusys.com.


'/>"/>
SOURCE Elusys Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Elusys Therapeutics Appoints Robert Gundel as Vice President of Research
2. Special coating greatly improves solar cell performance
3. Method to deliver molecules within embryonic stem cells improves differentiation
4. Perceptive Informatics Improves Clinical Site Monitoring Access and Flexibility With Portable USB Drive Capability
5. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. Oncologists Want to See Significant Improvement in Overall Survival Before Adopting Targeted Polytherapy in a First-Line Setting
8. Taxotere(R)-Based Chemotherapy Significantly Improved Overall Survival Compared With Standard Anthracycline-Based Chemotherapy in Early Stage Breast Cancer
9. CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
10. Start Licensing, Inc. Welcomes FDAs Finding of Safety of Food From Cloned Animals
11. Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... the QB3@953 life sciences incubator to accelerate ... The shared laboratory space at QB3@953 was created to ... key obstacle for many early stage organizations - access ... the sponsorship, Amgen launched two "Amgen Golden Ticket" awards, ...
(Date:6/22/2016)... NEW YORK , June 22, 2016 /PRNewswire/ ... the growing next generation sequencing (NGS) market include ... adoption of smaller sequencers.  More accessible and affordable ... led to growing demand for consumables including sample ... The Market for Sample Preparation for Next ...
(Date:6/22/2016)... BELLINGHAM, Washington, USA (PRWEB) , ... June 21, 2016 , ... ... — and without cutting into the tissue — promise to enable both compact, wearable ... information and from even deeper under the skin. , Recent work and visionary future ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016   The Weather Company , an IBM ... an industry-first capability in which consumers will be able to ... ask questions via voice or text and receive relevant information ... Marketers have long sought an advertising solution that ... be personal, relevant and valuable; and can scale across millions ...
(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):